RecruitingNCT06540833
Testing ITI-1284 or placebo for psychosis in Alzheimer’s disease
About this title
Read the official source — NCT06540833Medication studyAges 55+Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: from 55 years.
- Listed locations
- Anaheim and 68 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 15, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 370
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- Over 55 Years
- Official registry ID
- NCT06540833
- Official title
Show the full official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
Recruitment & locations
RecruitingAnaheim, United States · Los Alamitos, United States · Newport Beach, United States
53 more locations
- Orange, United States
- Walnut Creek, United States
- Bonita Springs, United States
- Brandon, United States
- Coral Springs, United States
- Delray Beach, United States
- Doral, United States
- Homestead, United States
- Maitland, United States
- Miami, United States
- Orlando, United States
- Sarasota, United States
- Tampa, United States
- Savannah, United States
- Toms River, United States
- Charlotte, United States
- Matthews, United States
- Cypress, United States
- San Antonio, United States
- Bellevue, United States
- Blagoevgrad, Bulgaria
- Cherven Bryag, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Vratsa, Bulgaria
- Zagreb, Croatia
- Brno, Czechia
- Hradec Králové, Czechia
- Prague, Czechia
- Arzignano, Italy
- Brescia, Italy
- Cefalù, Italy
- Tricase, Italy
- Bydgoszcz, Poland
- Katowice, Poland
- Ścinawa, Poland
- Bucharest, Romania
- Galati, Romania
- Sibiu, Romania
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Banská Bystrica, Slovakia
- Bratislava, Slovakia
- Košice, Slovakia
- Krompachy, Slovakia
- Vranov nad Topľou, Slovakia
- Albacete, Spain
- Zamora, Spain
- Zaragoza, Spain
- Czechia
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Does this study involve medication?
Yes. The study involves medication, including ITI-1284 and Placebo.
Who can participate?
Listed age limits: from 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....